BioSpace News Archive

GeneTx Biotherapeutics LLC today announced that it has received IRB approval from Rush University Medical Center in Chicago, IL to begin the “KIK-AS” (Knockdown of UBE3A-antisense in Kids with Angelman Syndrome) Phase 1/2 clinical study of GTX-102, an experimental antisense oligonucleotide being evaluated for the treatment of Angelman syndrome (AS).

WAT Medical is thrilled to announce the newest clinical study conducted for an anti-migraine device by the HeadaTerm, for the treatment of migraines

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a leading platform neurosurgery company, today announced a strategic agreement with PTC Therapeutics, Inc. (“PTC”).

ARMA Sport Inc. (“ARMA”), an action and adventure lifestyle-driven brand founded by action sports industry veterans from Oakley, Spy, Dragon, and Monster Energy, with seven-time AMA Supercross Champion and motocross legend Jeremy McGrath, proudly announces the launch of its sports nutrition performance and recovery products.

The global craniomaxillofacial (CMF) devices market is expected to grow at a sound pace over the next decade. The unprecedented advancements that have offset across the healthcare industry have become the basis for market growth.

The growing application of cryotherapy as an effective recovery intervention for athletes as a part of sport medicine has gathered popularity.

The global market for Cancer Biomarkers has been growing at a fast pace, owing to the research and development activities.

BOSTON , Feb. 14, 2020 /PRNewswire/ -- In response to severe storms and flooding in Kentucky , North Carolina , Oregon , Virginia , Washington and West Virginia , Blue Cross Blue Shield of Massachusetts (“Blue Cross”) is expediting access to care for members who may be affected by flooding in these six states. Blue Cross

Feb. 14, 2020 16:56 UTC DUBLIN, Ohio--( BUSINESS WIRE )-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that following the recently-announced funding transactions, the Company is back in compliance with the NYSE American’s continued listing standards. As previously reported, on August 14, 2018, the Company received a Deficien

Therap’s development disability software features tools for Florida APD providers to document Employment Stability Plans in accordance with the guidelines set forth within the Agency for Persons with Disabilities’ Developmental Disability Waiver Services Coverage and Limitations Handbook.